Anti-ISG15 (N-terminal) polyclonal antibody

Antibody Isotype

IgG

Species Reactivity

Mouse; Human

Immunogen

KLH conjugated synthetic peptide derived from the N terminus of Human ISG15.

Conjugate

Application Notes

WB: 1/100 - 1/500; ELISA: 1/1000; IHC-P: 10 μg/ml.

Alternative Names

ISG15; ISG15 ubiquitin-like modifier; G1P2, interferon, alpha inducible protein (clone IFI 15K); ubiquitin-like protein ISG15; IFI15; UCRP; ubiquitin cross-reactive protein; interferon-induced 15 kDa protein; interferon-induced 17 kDa protein; interferon-

Entrez Gene ID

UniProt ID

Antigen Description

Ubiquitin-like protein that is conjugated to intracellular target proteins after IFN-alpha or IFN-beta stimulation. Its enzymatic pathway is partially distinct from that of ubiquitin, differing in substrate specificity and interaction with ligating enzymes. ISG15 conjugation pathway uses a dedicated E1 enzyme, but seems to converge with the Ub conjugation pathway at the level of a specific E2 enzyme. Targets include STAT1, SERPINA3G/SPI2A, JAK1, MAPK3/ERK1, PLCG1, EIF2AK2/PKR, MX1/MxA, and RIG-1. Deconjugated by USP18/UBP43. Shows specific chemotactic activity towards neutrophils and activates them to induce release of eosinophil chemotactic factors. May serve as a trans-acting binding factor directing the association of ligated target proteins to intermediate filaments. May also be involved in autocrine, paracrine and endocrine mechanisms, as in cell-to-cell signaling, possibly partly by inducing IFN-gamma secretion by monocytes and macrophages. Seems to display antiviral activity during viral infections.In response to IFN-tau secreted by the conceptus, may ligate to and regulate proteins involved in the release of prostaglandin F2-alpha (PGF), and thus prevent lysis of the corpus luteum and maintain the pregnancy.

Pathway

Antiviral mechanism by IFN-stimulated genes; Cytokine Signaling in Immune system; ISG15 antiviral mechanism; Immune System; Innate Immune System; Interferon Signaling; Interferon alpha/beta signaling